Patents by Inventor John E. Macor

John E. Macor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ARYL AMIDE-BASED KINASE INHIBITORS
    Publication number: 20160016967
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Application
    Filed: February 6, 2014
    Publication date: January 21, 2016
    Inventors: Vivekananda M. Vrudhula, Carolyn Diane Dzierba, Joanne J. Bronson, John E. Macor, Susheel Jethanand Nara, Ramkumar Rajamani, Maheswaran Sivasamban Karatholuvhu
  • Selective NR2B antagonists
    Patent number: 9221796
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.
    Type: Grant
    Filed: January 5, 2015
    Date of Patent: December 29, 2015
    Assignee: Bristol-Myers Squibb Company
    Inventors: Dalton King, Lorin A. Thompson, III, Jianliang Shi, Srinivasan Thangathirupathy, Jayakumar Sankara Warrier, Imadul Islam, John E. Macor
  • QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS
    Publication number: 20150342935
    Abstract: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic ?7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.
    Type: Application
    Filed: August 6, 2015
    Publication date: December 3, 2015
    Inventors: James H. Cook, II, Ivar M. McDonald, Dalton King, Richard E. Olson, Nenghui Wang, Christiana I. Iwuagwu, F. Christopher Zusi, John E. Macor
  • COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION
    Publication number: 20150336975
    Abstract: The present disclosure provides a series of compounds of the formula (I) which modulate ?-amyloid peptide (?-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions affected by ?-amyloid peptide (?-AP) production.
    Type: Application
    Filed: August 3, 2015
    Publication date: November 26, 2015
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Kenneth M. Boy, Jason M. Guernon, John E. Macor, Richard E. Olson, Jianliang Shi, Lorin A. Thompson, III, Yong-Jin Wu, Li Xu, Yunhui Zhang, Dmitry S. Zuev
  • ()-3-((3,4)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders
    Patent number: 9187506
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the NR2B NMDA receptor and may be useful for the treatment of various disorders of the central nervous system.
    Type: Grant
    Filed: January 7, 2015
    Date of Patent: November 17, 2015
    Assignee: Bristol-Myers Squibb Company
    Inventors: Lorin A. Thompson, III, John E. Macor
  • (R)-3-((3S,4S)-3-FLUORO-4-(4-HYDROXYPHENYL)PIPERIDIN-1-YL)-1-(4-METHYLBENZYL)PYRROLIDIN-2-ONE AND ITS PRODRUGS FOR THE TREATMENT OF PSYCHIATRIC DISORDERS
    Publication number: 20150191496
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the NR2B NMDA receptor and may be useful for the treatment of various disorders of the central nervous system.
    Type: Application
    Filed: January 7, 2015
    Publication date: July 9, 2015
    Inventors: Lorin A. Thompson, III, John E. Macor
  • Selective NR2B Antagonists
    Publication number: 20150191452
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.
    Type: Application
    Filed: January 5, 2015
    Publication date: July 9, 2015
    Inventors: Dalton King, Lorin A. Thompson, III, Jianliang Shi, Srinivasan Thangathirupathy, Jayakumar Sankara Warrier, Imadul Islam, John E. Macor
  • COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION
    Publication number: 20150152089
    Abstract: The present disclosure provides a series of compounds of the formula (I) which modulate ?-amyloid peptide (?-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions affected by ?-amyloid peptide (?-AP) production.
    Type: Application
    Filed: February 6, 2015
    Publication date: June 4, 2015
    Inventors: Kenneth M. Boy, Jason M. Guernon, John E. Macor, Richard E. Olson, Jianliang Shi, Lorin A. Thompson, III, Yong-Jin Wu, Li Xu, Yunhui Zhang, Dmitry S. Zuev
  • 2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
    Patent number: 9045468
    Abstract: The compounds of the present invention are represented by the following 2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives having formula (I): where the carbon atom designated * is in the R or S configuration when n is 1 and the substituents X and R1-R7 are as defined herein.
    Type: Grant
    Filed: August 17, 2011
    Date of Patent: June 2, 2015
    Assignees: Albany Molecular Research, Inc., Bristol-Myers Squibb Company
    Inventors: Peter R. Guzzo, Shuang Liu, Kristen N. Ryan, Bruce F. Molino, Russell DeOrazio, Richard E. Olson, John E. Macor
  • QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS
    Publication number: 20150094309
    Abstract: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic ?7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.
    Type: Application
    Filed: December 18, 2014
    Publication date: April 2, 2015
    Inventors: James H. Cook, II, Ivar M. McDonald, Dalton King, Richard E. Olson, Nenghui Wang, Christiana I. Iwuagwu, F. Christopher Zusi, John E. Macor
  • Aryl ether-base kinase inhibitors
    Patent number: 8969564
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Grant
    Filed: February 24, 2014
    Date of Patent: March 3, 2015
    Assignee: Bristol-Myers Squibb Company
    Inventors: Vivekananda M. Vrudhula, Senliang Pan, Ramkumar Rajamani, John E. Macor, Joanne J. Bronson, Carolyn Diane Dzierba, Susheel Jethanand Nara, Maheswaran Sivasamban Karatholuvhu
  • Aryl lactam kinase inhibitors
    Patent number: 8901305
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Grant
    Filed: July 19, 2013
    Date of Patent: December 2, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Vivekananda M. Vrudhula, Senliang Pan, Ramkumar Rajamani, Susheel Jethanand Nara, Maheswaran Sivasamban Karatholuvhu, Tarun Kumar Maishal, Jonathan L. Ditta, Carolyn Diane Dzierba, Joanne J. Bronson, John E. Macor
  • Selective NR2B antagonists
    Patent number: 8841301
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, antagonists of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.
    Type: Grant
    Filed: September 24, 2012
    Date of Patent: September 23, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Dalton King, John E. Macor, Richard E. Olson, Christiana I. Iwuagwu, George N. Karageorge
  • Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands
    Publication number: 20140221377
    Abstract: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic ?7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.
    Type: Application
    Filed: April 7, 2014
    Publication date: August 7, 2014
    Inventors: James H. Cook, II, Ivar M. McDonald, Dalton King, Richard E. Olson, Nenghui Wang, Christiana I. Iwuagwu, F. Christopher Zusi, John E. Macor
  • Aryl Ether-Base Kinase Inhibitors
    Publication number: 20140179725
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Application
    Filed: February 24, 2014
    Publication date: June 26, 2014
    Inventors: Vivekananda M. Vrudhula, Senliang Pan, Ramkumar Rajamani, John E. Macor, Joanne J. Bronson, Carolyn Diane Dzierba, Susheel Jethanand Nara, Maheswaran Sivasamban Karatholuvhu
  • CGRP receptor antagonists
    Patent number: 8748429
    Abstract: The disclosure generally relates to the novel compounds of formula I, including pharmaceutically acceptable salts, which are CGRP receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using the compounds in the treatment of CGRP related disorders including migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases such as asthma, and chronic obstructive pulmonary disease (COPD).
    Type: Grant
    Filed: April 4, 2012
    Date of Patent: June 10, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Guanglin Luo, Gene M. Dubowchik, John E. Macor, Ling Chen
  • Selective NR2B antagonists
    Patent number: 8722670
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, antagonists of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.
    Type: Grant
    Filed: September 26, 2012
    Date of Patent: May 13, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Dalton King, Richard E. Olson, John E. Macor, Imadul Islam, Srinivasan Thangathirupathy, Jayakumar Sankara Warrier
  • Compounds for the reduction of ?-amyloid production
    Patent number: 8710061
    Abstract: The present disclosure provides a series of compounds of the formula (I) which modulate ?-amyloid peptide (?-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions affected by ?-amyloid peptide (?-AP) production.
    Type: Grant
    Filed: January 26, 2012
    Date of Patent: April 29, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kenneth M. Boy, Jason M. Guernon, John E. Macor, Richard E. Olson, Jianliang Shi, Lorin A. Thompson, III, Yong-Jin Wu, Li Xu, Yunhui Zhang, Dmitry S. Zuev
  • Aryl ether-base kinase inhibitors
    Patent number: 8703953
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Grant
    Filed: February 26, 2013
    Date of Patent: April 22, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Vivekananda M. Vrudhula, Senliang Pan, Ramkumar Rajamani, John E. Macor, Joanne J. Bronson, Carolyn Diane Dzierba, Susheel Jethanand Nara, Maheswaran Sivasamban Karatholuvhu
  • Aryl Lactam Kinase Inhibitors
    Publication number: 20140038999
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Application
    Filed: July 19, 2013
    Publication date: February 6, 2014
    Inventors: Vivekananda M. Vrudhula, Senliang Pan, Ramkumar Rajamani, Susheel Jethanand Nara, Maheswaran Sivasamban Karatholuvhu, Tarun Kumar Maishal, Jonathan L. Ditta, Carolyn Diane Dzierba, Joanne J. Bronson, John E. Macor